 Okay, so I'm here to introduce the first session and to tell you a little about the format of the session. So this session is going to have three speakers talking about the revision of the ACMG list. We're going to give them a chance to talk. We're going to have a few questions per person, but then at the end we'll have 20 minutes for group discussion of this topic. As most of you know, the ACMG had a list of 56 gene disease pairs. They considered actionable, and this was recently altered to a list of 59. And Wendy Chung was part of the panel that made the revision, so she's going to tell us about the 2.0 version of the test. And then Sharon Plahn is going to give a little feedback with a perspective on some of the genes that might have less evidence than you'd hope for. And Ian Krantz is going to give some perspective on a pediatric population needs with respect to this, and then hopefully we can have a robust discussion. So we'll start with Wendy.